253 related articles for article (PubMed ID: 31913706)
21. Cantharidin treatment inhibits hepatocellular carcinoma development by regulating the JAK2/STAT3 and PI3K/Akt pathways in an EphB4-dependent manner.
Zhu M; Shi X; Gong Z; Su Q; Yu R; Wang B; Yang T; Dai B; Zhan Y; Zhang D; Zhang Y
Pharmacol Res; 2020 Aug; 158():104868. PubMed ID: 32407961
[TBL] [Abstract][Full Text] [Related]
22. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
[TBL] [Abstract][Full Text] [Related]
23. DMAMCL exerts antitumor effects on hepatocellular carcinoma both in vitro and in vivo.
Yao S; Ye J; Yin M; Yu R
Cancer Lett; 2020 Jul; 483():87-97. PubMed ID: 32268165
[TBL] [Abstract][Full Text] [Related]
24. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
25. Matrine derivative WM130 inhibits hepatocellular carcinoma by suppressing EGFR/ERK/MMP-2 and PTEN/AKT signaling pathways.
Qian L; Liu Y; Xu Y; Ji W; Wu Q; Liu Y; Gao Q; Su C
Cancer Lett; 2015 Nov; 368(1):126-134. PubMed ID: 26259512
[TBL] [Abstract][Full Text] [Related]
26. THBS4 promotes HCC progression by regulating ITGB1 via FAK/PI3K/AKT pathway.
Guo D; Zhang D; Ren M; Lu G; Zhang X; He S; Li Y
FASEB J; 2020 Aug; 34(8):10668-10681. PubMed ID: 32567740
[TBL] [Abstract][Full Text] [Related]
27. Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma.
Wang H; Xu L; Zhu X; Wang P; Chi H; Meng Z
Oncol Rep; 2014 Oct; 32(4):1465-72. PubMed ID: 25070581
[TBL] [Abstract][Full Text] [Related]
28. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC
Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227
[TBL] [Abstract][Full Text] [Related]
29. Columbamine suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK1/2 MAPK signaling pathways.
Lin Z; Li S; Guo P; Wang L; Zheng L; Yan Z; Chen X; Cheng Z; Yan H; Zheng C; Zhao C
Life Sci; 2019 Feb; 218():197-204. PubMed ID: 30582951
[TBL] [Abstract][Full Text] [Related]
30. Identification of a new TRAF6 inhibitor for the treatment of hepatocellular carcinoma.
Li N; Luo L; Wei J; Liu Y; Haque N; Huang H; Qi Y; Huang Z
Int J Biol Macromol; 2021 Jul; 182():910-920. PubMed ID: 33865893
[TBL] [Abstract][Full Text] [Related]
31. Rap2B knockdown suppresses malignant progression of hepatocellular carcinoma by inactivating the PTEN/PI3K/Akt and ERK1/2 pathways.
Zhu L; Sun Y; Zhang S; Wang L
Mol Cell Biochem; 2020 Mar; 466(1-2):55-63. PubMed ID: 32052247
[TBL] [Abstract][Full Text] [Related]
32. Polydatin executes anticancer effects against glioblastoma multiforme by inhibiting the EGFR-AKT/ERK1/2/STAT3-SOX2/Snail signaling pathway.
Chen Y; Niu J; Li L; Li Z; Jiang J; Zhu M; Dong T; Zhang J; Shi C; Xu P; Lu Y; Jiang Y; Liu P; Chen W
Life Sci; 2020 Oct; 258():118158. PubMed ID: 32750435
[TBL] [Abstract][Full Text] [Related]
33. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
[TBL] [Abstract][Full Text] [Related]
34. LINC01133 aggravates the progression of hepatocellular carcinoma by activating the PI3K/AKT pathway.
Zheng YF; Zhang XY; Bu YZ
J Cell Biochem; 2019 Mar; 120(3):4172-4179. PubMed ID: 30548306
[TBL] [Abstract][Full Text] [Related]
35. Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway.
Wang H; Zhang C; Xu L; Zang K; Ning Z; Jiang F; Chi H; Zhu X; Meng Z
Oncotarget; 2016 Apr; 7(15):20193-208. PubMed ID: 26958938
[TBL] [Abstract][Full Text] [Related]
36. Alpinia oxyphylla oil induces apoptosis of hepatocellular carcinoma cells via PI3K/Akt pathway in vitro and in vivo.
Hui F; Qin X; Zhang Q; Li R; Liu M; Ren T; Zhao M; Zhao Q
Biomed Pharmacother; 2019 Jan; 109():2365-2374. PubMed ID: 30551496
[TBL] [Abstract][Full Text] [Related]
37. MiR-6875-3p promotes the proliferation, invasion and metastasis of hepatocellular carcinoma via BTG2/FAK/Akt pathway.
Xie Y; Du J; Liu Z; Zhang D; Yao X; Yang Y
J Exp Clin Cancer Res; 2019 Jan; 38(1):7. PubMed ID: 30621734
[TBL] [Abstract][Full Text] [Related]
38. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma.
Huang JL; Cao SW; Ou QS; Yang B; Zheng SH; Tang J; Chen J; Hu YW; Zheng L; Wang Q
Mol Cancer; 2018 May; 17(1):93. PubMed ID: 29803224
[TBL] [Abstract][Full Text] [Related]
39. LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway.
Song X; Wang J; Zheng T; Song R; Liang Y; Bhatta N; Yin D; Pan S; Liu J; Jiang H; Liu L
Mol Cancer; 2013 Oct; 12(1):114. PubMed ID: 24093956
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive anti-tumor effect of Brusatol through inhibition of cell viability and promotion of apoptosis caused by autophagy via the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
Ye R; Dai N; He Q; Guo P; Xiang Y; Zhang Q; Hong Z; Zhang Q
Biomed Pharmacother; 2018 Sep; 105():962-973. PubMed ID: 30021391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
